Boston Scientific's Q3 Confirms Reset: Management Sees 2027 as Trough

What happened

Boston Scientific's third-quarter results validated the market's fears, as the cyber disruption reduced growth and earnings, prompting management to cut 2026 guidance again and explicitly frame 2027 as the cycle's trough. The company's performance confirms that the operational setback compounded existing pressures in WATCHMAN and electrophysiology, which were already decelerating before the cyberattack. Management's commentary suggests they do not expect a near-term recovery, which undermines the thesis that the rest of the portfolio could offset weak franchises. Although operations have been restored and insiders have been buying shares, the credibility gap remains wide, and the stock's depressed valuation may be a value trap rather than an opportunity. The Q3 report provides little evidence that the key growth engines are re-accelerating, so a sustained recovery likely hinges on 2028 or later catalysts.

Implication

The Q3 results reinforce that Boston Scientific is in a prolonged reset phase, with management itself guiding to 2027 as the trough, which reduces the probability of the base case of portfolio resilience. The bear scenario, where WATCHMAN and EP continue to lose share and margins slip, becomes more plausible, potentially pushing the stock toward the $38 level. However, the company's strong balance sheet and the cluster of insider buying provide some downside support, and the current price may already discount much of the bad news. Absent a clear catalyst, such as WATCHMAN re-acceleration or EP stabilization, the risk-reward is not attractive for new positions. We maintain our WAIT rating but would consider trimming above $50 and only consider entering near $39 if we see signs of operational improvement.

Thesis delta

The new information shifts the thesis modestly more bearish: the confirmation of a 2027 trough and another guidance cut reduce confidence in the base case scenario and increase the likelihood of the bear case. However, the stock's already depressed price and insider buying suggest that downside may be limited if management executes on restructuring and cost cuts. Therefore, we maintain WAIT but with lower conviction on upside, and we would require evidence of WATCHMAN and EP re-acceleration before upgrading.